Unibest
← Back to patent-cliff list

Dabrafenib Mesylate

Tier B — Position early

Dabrafenib Mesylate · all drugs expiring in 2029 →

GSK
Originator
2013
First approval
2029
Expiry (public)
$2.21B ▲
Peak sales
Small molecule
Type

Targets：C-Raf, B-raf

Brand：Taffiner, Tafinlar, Tafinra, Tafinrar

Indications (approved)：Thyroid cancer, Colorectal cancer, Glioma, Anaplastic thyroid cancer, Solid tumour, Non-small cell lung cancer, Melanoma

Regional status

US
Approved
2013-05-29
EU
Approved
2013-08-26
China
Approved
2019-12-18
Japan
Approved
2016-03-28

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 2Steps 6 · Total yield 2.39 g
Synthetic routes & intermediates Route 2
CodeCAS No.Intermediate
DABF-00260230-36-6Available2,6-difluorobenzene-1-sulfonyl chloride
DABF-005630-22-8Available2,2-dimethylpropanethioamide
DABF-0081195768-18-3Availablemethyl 3-amino-2-fluorobenzoate
DABF-0091195768-19-4Availablemethyl 3-(2,6-difluorophenylsulfonamido)-2-fluorobenzoate
DABF-01013036-57-2Available2-chloro-4-methylpyrimidine
DABF-0111195768-20-7AvailableN-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
DABF-0121622082-84-1AvailableN-(3-(2-bromo-2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
DABF-0131195768-23-0AvailableN-(3-(2-(tert-butyl)-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
OptimisedRoute 1Steps 5 · Total yield 3.58 g
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
DABF-0011567366-22-6Availableethyl 3-(3-amino-2-fluorophenyl)-3-oxopropanoate
DABF-00260230-36-6Available2,6-difluorobenzene-1-sulfonyl chloride
DABF-0031567366-18-0Availableethyl 3-(3-(2,6-difluorophenylsulfonamido)-2-fluorophenyl)-3-oxopropanoate
DABF-005630-22-8Available2,2-dimethylpropanethioamide
DABF-0061567366-20-4Availableethyl 2-(tert-butyl)-4-(3-(2,6-difluorophenylsulfonamido)-2-fluorophenyl)thiazole-5-carboxylate
DABF-0071567366-21-5AvailableN-(3-(5-acetyl-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

Frequently asked questions

What are the approved indications of Dabrafenib Mesylate?

Approved indications include: Thyroid cancer, Colorectal cancer, Glioma, Anaplastic thyroid cancer, Solid tumour, Non-small cell lung cancer, Melanoma.

When does the Dabrafenib Mesylate patent expire?

Based on public sources, the Dabrafenib Mesylate patent expires in 2029.

How many synthesis routes are recorded for Dabrafenib Mesylate?

2 synthesis routes are recorded; the shortest is 5 steps with 3.58 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Dabrafenib Mesylate intermediates?

12 intermediate CAS of Dabrafenib Mesylate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Dabrafenib Mesylate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29